




Instance: composition-en-a321c1bbb3d0ca5c622bbbc9c0607a43
InstanceOf: CompositionUvEpi
Title: "Composition for beromun Package Leaflet"
Description:  "Composition for beromun Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/99/097/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa321c1bbb3d0ca5c622bbbc9c0607a43)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - beromun"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Beromun is and what it is used for </li>
<li>What you need to know before you use Beromun </li>
<li>How to use Beromun </li>
<li>Possible side effects </li>
<li>How to store Beromun </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What beromun is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What beromun is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Beromun contains the active substance tasonermin (tumor necrosis factor alfa-1a), produced by 
recombinant DNA technology. It belongs to a class of medicines known as immunostimulants, which 
help your body s immune system fight cancer cells. </p>
<p>Beromun is used, together with melphalan containing medicine, for the treatment of soft tissue 
sarcoma of the arms and legs. By reducing the size of the tumour, the treatment is intended to facilitate 
the removal of the tumor by surgery or to prevent severe damage to the surrounding healthy tissue and 
thus to delay or prevent the need for arm or leg amputation.  </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take beromun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take beromun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Beromun 
- if you are allergic to tasonermin or any of the other ingredients of this medicine (listed in 
section 6). 
- if you have significant heart problems 
- if you have severe lung disease 
- if you have or have recently had a stomach ulcer 
- if you have too low numbers of blood cells or bleeding problems 
- if you have moderate to severe liver or kidney disease 
- if you cannot use vasopressors (used to increase low blood pressure), anticoagulants (used to 
prevent blood clotting) or radioactive tracers 
- if you are also using medicines with heart toxicity<br />
- if you have raised levels of calcium in your blood 
- if you have certain infections which do not respond to antibiotics 
- if you have severe swelling of the affected arm or leg due to local fluid build-up, or severe fluid 
build-up in the abdomen 
- if you are pregnant or planning to become pregnant. 
- if you are breast-feeding, you must stop for at least seven days after receiving Beromun </p>
<p>Warnings and precautions<br />
Beromun will be administered by a doctor who is experienced and skilled in isolated limb perfusion 
(ILP). This technique ensures that Beromun is kept within the affected arm or leg. It is important that 
it does not reach other parts of your body, because this so-called systemic leakage could cause serious 
side effects on the main organs of the body.  </p>
<p>During the IPL and the seven to ten day period afterwards you will need to stay in hospital, your 
doctor will carefully monitor your blood pressure, circulation and any side effects. You may have to 
stay in an intensive care unit (ICU) directly after the ILP for a short time. </p>
<p>A condition called  compartment syndrome  may develop within the first three days after Beromun 
administration. Symptoms of muscle damage at the perfused limb include pain, swelling, as well as 
neurological symptoms (e. g. paraesthesia, paralysis), all of which should be reported immediately to 
the attending doctor. </p>
<p>Other medicines and Beromun 
Tell your doctor if you are using,  have recently used or might use any other medicines. In particular, 
you should tell your doctor if you are using medicines to lower blood pressure (to treat hypertension). </p>
<p>For ILP, you will also receive other medicines to control pain, fever, blood pressure and blood 
clotting, as well as general anaesthesia. </p>
<p>Pregnancy and breast-feeding 
You must not use Beromun if you are pregnant. 
You must not breast-feed for at least seven days after treatment with Beromun. </p>
<p>Driving and using machines 
Not relevant </p>
<p>Beromun contains sodium 
This medicine contains 151.27 mg (6.58mmol) sodium in each recommended dose. This is equivalent 
to 7.6% of the recommended maximum daily dietary intake of sodium for an adult. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take beromun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take beromun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Beromun will be administered by isolated limb perfusion (ILP), together with the anti-tumour agent 
melphalan. This will occur whilst you are unconscious, under the influence of a general anaesthetic. </p>
<p>The blood flow to and from your affected limb will be stopped using a tourniquet. Blood, supplied 
with oxygen by a heart and lung machine, is pumped into your affected limb via a catheter in the main 
artery, while it is drained (pumped out) from the main vein. Beromun and then melphalan are injected 
into this circuit, over a total of 90 minutes the affected limb will be exposed to Beromun. </p>
<p>The recommended dose of Beromun depends on the affected limb, usually 3 mg for the arm and 4 mg 
for the leg. Beromun powder has to be dissolved before use. The resulting solution will be 
administered into an artery in your affected arm or leg by ILP for an initial period of 30 minutes.<br />
After that, melphalan will be added and the ILP continued for another 60 minutes.<br />
Finally, your limb will be washed out to remove the rest of Beromun and melphalan. </p>
<p>ILP allows that tumour cells in your limb can be exposed to a very high dose of Beromun and 
melphalan, enhancing their anti-tumour effect, but without reaching the rest of the body, where they 
could cause serious side effects.  </p>
<p>You will usually not receive a second ILP with Beromun. If you do, this will not be until at least six 
weeks after your first ILP. </p>
<p>If you use more Beromun than you should 
As Beromun is always administered by experienced and qualified hospital doctors, accidental 
overdose is extremely unlikely. However, should this occur, your doctor will immediately wash out 
your affected limb to remove Beromun, and the ILP will be stopped. If there is any risk of serious side 
effects, your doctor will immediately transfer you to an intensive care unit to closely monitor you and 
start adequate treatment. </p>
<p>If there is significant systemic leakage of Beromun 
If more than 10% of your Beromun dose reaches the main part of your body, your doctor will take 
similar measures as in the case of overdose.  </p>
<p>If you have any further questions on the use of this product, ask your doctor. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Side effects may be caused by Beromun, melphalan, the ILP technique or a combination of these 
factors. Some of the side effects can be serious, particularly if Beromun reaches other parts of your 
body (systemic leakage). In approximately 2% of cases, Beromun may cause tissue damage in your 
affected arm or leg which is severe enough to require amputation. If there is any risk of serious side 
effects, your doctor will immediately transfer you to an intensive care unit to closely monitor you and 
start adequate treatment. </p>
<p>The following side effects were observed during treatment with this medicine (grouped by how likely 
they are to happen). </p>
<p>Very common (may affect more than 1 in 10 people) 
- disturbances in your heart beat (arrhythmia) 
- feeling sick, vomiting 
- liver damage 
- blistering of the skin 
- fever (usually mild to moderate), chills 
- pain in the affected arm or leg 
- tiredness (fatigue) </p>
<p>Common (may affect up to 1 in 10 people) 
- infections 
- local wound infections 
- reductions in numbers of certain white blood cells and platelets 
- hypersensitivity (allergic) reactions 
- nerve damage 
- decreased consciouness<br />
- headache 
- heart problems which can cause shortness of breath or ankle swelling 
- blood clot formation in the artery or vein of the affected arm or leg (thrombosis) 
- low blood pressure, shock 
- severe breathing problems 
- constipation, diarrhoea 
- skin necrosis (death of skin cells) in the affected arm or leg 
- swelling of the ankles, feet or fingers caused by fluid build up in the affected arm or leg 
-  compartment syndrome , a medical condition characterised by pain, swelling and neurological 
symptoms, as well as muscle damage in the affected arm or leg 
- muscle pain 
- protein in urine 
- night sweats 
- tissue necrosis (death of tissue cells) in the affected arm or leg, which is severe enough to 
require amputation </p>
<p>Uncommon (may affect up to 1 in 100 people) 
- blood poisoning (sepsis) 
- fluid in the lungs 
- stomach ache 
- inflammation of the gastric mucosa (gastritis)<br />
- temporary loss of finger or toe nails of the affected arm or leg 
- kidney failure 
- blood tests showing changes in the way the kidneys are working 
- narrowing or closing of limb vessels carrying blood from the heart </p>
<p>Reporting of side effects 
If you get any side effects talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side effects you can help provide more information on the safety of this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store beromun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store beromun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C - 8 C). Upon reconstitution the product should be used immediately. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Beromun contains 
- The active substance is tasonermin. Each vial contains 1 mg tasonermin. The content of one vial 
of Beromun powder should be reconstituted with 5.3 ml sterile 0.9% sodium chloride solution 
for injection<br />
- The other ingredients (excipient(s)) are sodium dihydrogen phosphate dihydrate, disodium 
phosphate dodecahydrate and human serum albumin. </p>
<p>What Beromun looks like and contents of the pack 
Beromun is a white to off-white powder for solution for infusion (powder for infusion) supplied in a 
glass vial with rubber stopper and sealed with aluminium flip-off cap. 
Each pack contains 4 vials of powder. </p>
<p>Marketing Authorisation Holder<br />
BELPHARMA s.a. 
2, Rue Albert 1er<br />
L-1117 Luxembourg 
Grand Duchy of Luxembourg </p>
<p>Manufacturer<br />
Eumedica NV 
Chemin de Nauwelette 1 
B-7170 Manage 
Belgium<br />
For any information about this medicine, please contact the Marketing Authorisation Holder: </p>
<p>BELPHARMA s.a. 
2, Rue Albert 1er<br />
L-1117 Luxembourg 
Grand Duchy of Luxembourg 
Tel : +352 27403This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-a321c1bbb3d0ca5c622bbbc9c0607a43
InstanceOf: CompositionUvEpi
Title: "Composition for beromun Package Leaflet"
Description:  "Composition for beromun Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/99/097/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa321c1bbb3d0ca5c622bbbc9c0607a43)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - beromun"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse  <br />
2. Det skal du vide, før du begynder at bruge Beromun 
3. Sådan skal du bruge Beromun 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What beromun is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What beromun is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Beromun indeholder det aktive stof tasonermin (tumornekrosefaktor alfa-1a), der fremstilles ved 
hjælp af rekombinant DNA-teknologi. Det tilhører en gruppe lægemidler, der er kendt som 
immunstimulanter. Disse hjælper dit immunsystem med at bekæmpe kræftceller. </p>
<p>Beromun bruges sammen med lægemidlet melfalan til at behandle bløddelssvulster i arme eller ben. 
Behandlingen gives for at mindske størrelsen af svulsten og dermed gøre det lettere at fjerne svulsten 
kirurgisk. Den gives også for at forebygge alvorlige skader på det omgivende sunde væv, så 
amputation af armen eller benet kan udsættes eller helt undgås. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take beromun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take beromun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Beromun:</p>
<ul>
<li>hvis du er allergisk over for tasonermin eller et af de øvrige indholdsstoffer i Beromun (angivet 
i punkt 6) </li>
<li>hvis du har alvorlige hjerteproblemer  </li>
<li>hvis du lider af en alvorlig lungesygdom </li>
<li>hvis du har eller for nylig har haft mavesår </li>
<li>hvis antallet af blodlegemer er for lav eller der er andre blødningsproblemer </li>
<li>hvis du lider af lever- eller nyresygdomme i moderat til svær grad </li>
<li>hvis du ikke må tage lægemidler mod for lavt blodtryk (karkontraherende medicin), 
antikoagulanter (lægemidler, der bruges til at forhindre blodstørkning) eller radioaktive 
sporstoffer </li>
<li>hvis du samtidig behandles med lægemidler, som påvirker hjertet toksisk (f.eks. antracykliner) </li>
<li>hvis du har en forhøjet koncentration af kalcium i blodet </li>
<li>hvis du lider af infektioner, som ikke reagerer på behandling med antibiotika </li>
<li>hvis dures syge arm eller ben er hævet på grund af lokal væskeansamling, eller du har en svær 
væskeansamling i bughulen </li>
<li>hvis du er gravid eller planlægger at blive gravid  </li>
<li>Du må ikke amme i mindst 7 dage efter Beromun-behandlingen 
Advarsler og forsigtighedsregler 
Beromun vil blive givet af en læge, som har viden og erfaring i isoleret ekstremitetsperfusion (ILP).<br />
Denne teknik sørger for, at Beromun forbliver i den syge arm eller det syge ben. Det er vigtigt, at 
stoffet ikke kommer ud i andre dele af kroppen, da denne såkaldte systemiske lækage kan give 
alvorlige bivirkninger i kroppens organer. </li>
</ul>
<p>Du skal være indlagt på hospitalet under IPL-behandlingen og i 7-10 dage efter. I den periode vil 
lægerne nøje overvåge dit blodtryk og kredsløb og holde øje med alle bivirkninger. Du skal muligvis 
tilbringe en kortere periode på intensivafdelingen, umiddelbart efter ILP. </p>
<p>En lidelse, der hedder "kompartment-syndrom" kan udvikle sig inden for de tre første dage efter 
indgift af Beromun. Symptomerne på muskelskade i det behandlede ben eller arm er smerter, hævelse 
samt neurologiske symptomer (nervesymptomer, f.eks. føleforstyrrelser, lammelser). Du skal straks 
give besked om disse symptomer til en læge. </p>
<p>Brug af anden medicin sammen med Beromun 
Fortæl det altid til lægen, hvis du bruger anden medicin eller har gjort det for nylig. Det gælder især, 
hvis du tager medicin, der sænker blodtrykket. </p>
<p>Ved behandlingen med ILP vil du også få lægemidler, der virker på smerter, feber, blodtryk og 
blodets størkningsevne, og du vil komme i fuld bedøvelse. </p>
<p>Graviditet og amning 
Du må ikke få Beromun, hvis du er gravid.<br />
Du må ikke amme i mindst 7 dage efter behandling med Beromun. </p>
<p>Trafik- og arbejdssikkerhed 
Ikke relevant. </p>
<p>Beromun indeholder natrium 
Den rekonstituerede medicin indeholder op til 151,27 mg (6,58 mmol) natrium per anbefalet dosis. 
Hvis du er på natrium- eller saltfattig diæt, skal du tage hensyn hertil. </p>
<p>Beholderen indeholder latexgummi 
Denne lægemiddelbeholder indeholder naturgummi/latex. Kan medføre svære allergiske reaktioner. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take beromun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take beromun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Beromun vil blive indgivet ved hjælp af isoleret ekstremitetsperfusion (ILP) sammen med kræftmidlet 
melfalan. Dette vil foregå, mens du er under fuld bedøvelse (narkose). </p>
<p>Blodforsyningen fra og til den syge arm/det sygeben vil blive standset ved hjælp af en årepresse. 
Blodet forsynes med ilt ved hjælp af hjerte/lungemaskine og pumpes ind i den syge arm/det syge ben 
via et kateter i hovedåren (arterien), mens blodet ledes ud via et andet kateter i hovedvenen. Beromun 
og derefter melfalan bliver sprøjtet ind i dette kredsløb. Den syge arm/det syge ben vil blive udsat for 
Beromun i 90 minutter i alt.  </p>
<p>Den anbefalede Beromun-dosis afhænger af legemsdelen - den er sædvanligvis 3 mg, hvis det er 
armen, og 4 mg, hvis det er benet. </p>
<p>Beromun-pulver opløses før anvendelsen. Den færdige opløsning vil blive indgivet i en blodåre i den 
syge arm eller det syge ben ved hjælp af ILP-teknik over en periode på 30 minutter.  </p>
<p>Herefter indgives også melfalan, og ILP-behandlingen vil fortsætte i yderligere 60 minutter.  </p>
<p>Behandlingen afsluttes med, at arm eller ben skylles igennem for at fjerne rester af Beromun og 
melfalan i årerne.  </p>
<p>ILP-teknikken gør, at tumorcellerne i armen eller benet kan udsættes for en meget høj dosis Beromun 
og melfalan, hvilket øger deres anti-tumor-virkning, og det på en sådan måde, at stofferne ikke 
kommer ud i resten af kroppen, hvor de kunne forårsage alvorlige bivirkninger.   </p>
<p>Sædvanligvis får man kun én behandling med ILP. Hvis du skal behandles mere end én gang, går der 
mindst 6 uger fra din første ILP-behandling. </p>
<p>Hvis du har brugt for meget Beromun 
Da Beromun altid administreres af erfarne og kvalificerede hospitalslæger, er overdosering som følge 
af uheld uhyre sjælden. Skulle det imidlertid ske, vil lægen straks skylle årerne i armen/benet igennem 
for at fjerne Beromun, og ILP vil blive bragt til ophør. Hvis der er nogen som helst risiko for alvorlige 
bivirkninger, vil din læge straks få dig overført til intensivafdelingen på hospitalet til overvågning og 
påbegyndelse af en passende behandling. </p>
<p>Hvis der sker en betydningsfuld systemisk lækage af Beromun 
Hvis mere end 10 % af Beromun-dosis når ud i resten af kroppen (også kaldet systemisk lækage), 
tager lægen samme forholdsregler som ved overdosering. </p>
<p>Spørg lægen, hvis der er noget, du er i tvivl om.  </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Bivirkningerne kan forårsages af Beromun, af melfalan, af ILP-teknikken eller en kombination af 
disse. Nogle af bivirkningerne kan være alvorlige, især hvis Beromun når ud i andre dele af kroppen 
(systemisk lækage). I ca. 2 % af tilfældene kan Beromun forårsage vævsskader i den syge arm eller 
ben, der er så alvorlige, at amputation bliver nødvendig. Hvis der er risiko for alvorlige bivirkninger, 
vil din læge omgående overføre dig til en intensivafdeling på hospitalet for at overvåge dig nøje og 
starte passende behandling. </p>
<p>Følgende bivirkninger blev observeret under behandlingen med denne medicin (grupperet efter hvor 
sandsynlige de er). </p>
<p>Meget almindelig (kan forekomme hos mere end 1 ud af 10 personer) 
- uregelmæssig hjerterytme (arytmi) 
- kvalme, opkastning 
- leverskade 
- blærer på huden 
- feber (normalt let til moderat), kulderystelser<br />
- smerte i den berørte arm eller ben 
- træthed </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer) 
- infektioner 
- lokale sårinfektioner 
- nedsat antal hvide blodlegemer og blodplader 
- overfølsomhedsreaktioner 
- nerveskader 
- bevidsthedssvækkelse 
- hovedpine 
- problemer med hjertet, hvilket kan give åndenød og hævede ankler 
- blodprop i åre (arterie eller vene) på den berørte arm eller ben (trombose) 
- lavt blodtryk, shock 
- alvorlige åndedrætsproblemer 
- forstoppelse, diarré 
- hudnekrose (hudcellerne dør) i den berørte arm eller ben 
- hævede ankler, fødder eller fingre på grund af væskeophobning i den berørte arm eller ben 
- kompartmentsymdrom, en lidelse, der er karakteriseret ved smerter, hævelse og 
nervesymptomer, såvel som muskelskade i den berørte arm eller ben 
- muskelsmerte 
- protein i urinen 
- nattesved 
- vævsnekrose (vævscellerne dør) i den berørte arm eller ben, hvilket i alvorlige situationer kan 
føre til amputation </p>
<p>Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer) 
- blodforgiftning (sepsis) 
- væske i lungerne 
- mavesmerter 
- vævsirritation (inflammation) af maveslimhinden (gastrit) 
- midlertidigt tab af finger- eller tånegle på den berørte arm eller ben 
- nyresvigt 
- blodtest kan vise ændringer i nyrefunktionen 
- forsnævring eller lukning af arterier (blodårer, der transporterer blodet fra hjertet) i arme eller 
ben.  </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge. Dette gælder også mulige bivirkninger, som 
ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også indberette bivirkninger 
direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at 
indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette 
lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store beromun"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store beromun"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og på hætteglasset efter Exp. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2 °C -8 °C). Efter rekonstitution skal produktet bruges med det samme. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Beromun indeholder:</p>
<ul>
<li>Aktivt stof: tasonermin. Hvert hætteglas indeholder 1 mg tasonermin. Indholdet af et hætteglas 
med Beromun-pulver skal rekonstitueres med 5,3 ml steril 0,9 % natriumchlorid injektionsvæske, 
opløsning. </li>
<li>Øvrige indholdsstoffer (hjælpestoffer): natriumdihydrogenphosphatdihydrat, dinatriumphosphat-
dodecahydrat  og human serumalbumin. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Beromun er et hvidt til offwhite-farvet pulver, til brug i en infusionsopløsning (pulver til 
infusionsvæske). Det leveres i et hætteglas med gummipropog forseglet med et aluminiums-flip-off-
låg.<br />
Hver pakning indeholder 4 hætteglas med pulver. </p>
<p>Indehaver af markedsføringstilladelsen 
BELPHARMA s.a. 
2, Rue Albert 1er<br />
L-1117 Luxembourg 
Storhertugdømmet Luxembourg </p>
<p>Fremstiller 
Eumedica NV 
Chemin de Nauwelette 1 
B-7170 Manage <br />
Belgien  </p>
<p>Med hensyn til yderligere oplysninger om dette lægemiddel bedes man rette henvendelse til 
indehaveren af markedsføringstilladelsen: </p>
<p>BELPHARMA s.a. 
2, Rue Albert 1er<br />
L-1117 Luxembourg 
Storhertugdømmet Luxembourg 
Tel : +352 27403 
Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>De kan finde yderligere oplysninger om Beromun på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>Denne indlægsseddel findes på alle EU-/EØS-sprog på Det Europæiske Lægemiddelagenturs 
hjemmeside. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-a321c1bbb3d0ca5c622bbbc9c0607a43
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for beromun Package Leaflet for language en"
Description: "ePI document Bundle for beromun Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-a321c1bbb3d0ca5c622bbbc9c0607a43"
* entry[0].resource = composition-en-a321c1bbb3d0ca5c622bbbc9c0607a43

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa321c1bbb3d0ca5c622bbbc9c0607a43"
* entry[=].resource = mpa321c1bbb3d0ca5c622bbbc9c0607a43
                            
                    
Instance: bundlepackageleaflet-da-a321c1bbb3d0ca5c622bbbc9c0607a43
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for beromun Package Leaflet for language da"
Description: "ePI document Bundle for beromun Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-a321c1bbb3d0ca5c622bbbc9c0607a43"
* entry[0].resource = composition-da-a321c1bbb3d0ca5c622bbbc9c0607a43

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpa321c1bbb3d0ca5c622bbbc9c0607a43"
* entry[=].resource = mpa321c1bbb3d0ca5c622bbbc9c0607a43
                            
                    



Instance: mpa321c1bbb3d0ca5c622bbbc9c0607a43
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Beromun 1 mg powder for solution for infusion"
Description: "Beromun 1 mg powder for solution for infusion"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/99/097/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Beromun 1 mg powder for solution for infusion"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: a321c1bbb3d0ca5c622bbbc9c0607a43ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "beromun"

* status = #current
* mode = #working

* title = "List of all ePIs associated with beromun"

* subject = Reference(mpa321c1bbb3d0ca5c622bbbc9c0607a43)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#beromun "beromun"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-a321c1bbb3d0ca5c622bbbc9c0607a43) // beromun en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-a321c1bbb3d0ca5c622bbbc9c0607a43) // beromun da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-a321c1bbb3d0ca5c622bbbc9c0607a43
InstanceOf: List

* insert a321c1bbb3d0ca5c622bbbc9c0607a43ListRuleset
    